coronary stenosis

El reemplazo transcatéter en válvulas bicúspides suma evidencia pero continúan los desafíos

TAVR in Bicuspid Has the Same Results in Surgery at Hospital Level

Courtesy of Dr. Carlos Fava. Bicuspid aortic stenosis patients (bicuspid AS) represent a small group and have not been included in the larger transcatheter aortic valve replacement (TAVR) studies, since they present different morphology and asymmetric calcification, which might come along with more paravalvular leak and less accurate positioning. Between 2012 and 2016, 475,315 patients<a href="https://solaci.org/en/2019/09/24/tavr-in-bicuspid-has-the-same-results-in-surgery-at-hospital-level/" title="Read more" >...</a>

Los balones farmacológicos pasaron la prueba del tiempo en territorio femoropoplíteo

Drug Coated Balloons vs. Drug Eluting Stents in Primary PCI

There might come the time when we are finally able to leave nothing behind, at least in the context of primary PCI. The REVELATION study, soon to be published in J Am Coll Cardiol Intv, has shown that paclitaxel coated balloons resulted non inferior to drug eluting stents (DES) in terms of FFR (fractional flow<a href="https://solaci.org/en/2019/09/19/drug-coated-balloons-vs-drug-eluting-stents-in-primary-pci/" title="Read more" >...</a>

ESC 2019 | CLARIFY: Los síntomas predicen riesgo solamente en pacientes con infarto previo

ESC 2019 | CLARIFY: Symptoms Predict Risk Only in Patients with Prior MI

The 5-year follow up of patients with chronic stable angina (or as the guidelines currently call it chronic coronary syndrome) indicate the risk of cardiovascular death or non-fatal MI is quite low, but risk factor control is still fairly poor. This information comes from the CLARIFY study, presented at ESC 2019 and published simultaneously in<a href="https://solaci.org/en/2019/09/09/esc-2019-clarify-symptoms-predict-risk-only-in-patients-with-prior-mi/" title="Read more" >...</a>

ESC 2019 | Complete: La evidencia definitiva para infartos con múltiples vasos

ESC 2019 | COMPLETE: Definitive Evidence for Infarction with Multivessel Disease

For patients with ST-segment elevation acute myocardial infarction and multivessel disease beyond the culprit artery, complete revascularization is superior to culprit-only treatment as regards the final endpoint, a composite of cardiovascular death, infarction, and ischemia-driven revascularization over a mean follow-up of 3 years. This information derives from long-awaited randomized study COMPLETE, finally presented at the<a href="https://solaci.org/en/2019/09/05/esc-2019-complete-definitive-evidence-for-infarction-with-multivessel-disease/" title="Read more" >...</a>

Sinus Aspiration against Contrast Induced Kidney Injury

Mechanisms of Post PCI Persistent Angina

Angina persistence or recurrence after PCI can affect between 20 to 40% of patients in the short and mid-term. This might be true despite PCI optimization using FFR, intravascular ultrasound and the latest generation stents. This problem is associated with high healthcare cost, which can double in patients with recurrent or persistent angina compared against<a href="https://solaci.org/en/2019/08/22/mechanisms-of-post-pci-persistent-angina/" title="Read more" >...</a>

La prudencia es buena consejera para decidir una transfusión en el TAVI

FDA Expands TAVR Indication to Low-Risk Patients

Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. The US Food and Drug Administration (FDA) has approved and expanded the indication for the Evolut series (Medtronic) and the Sapien 3 and<a href="https://solaci.org/en/2019/08/21/fda-expands-tavr-indication-to-low-risk-patients/" title="Read more" >...</a>

FFR para guiar la revascularización en SCA

FFR to Predict CABG Result: All Benefits in a Population Much Too Pure?

Coronary artery bypass graft (CABG) anastomosed to one vessel with normal or nearly normal fractional flow reserve (FFR) have poorer graft patency at one year compared against anastomosed grafts to vessels with functionally significant lesions shown by FFR. However, the recent study FARGO (Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization) did not show<a href="https://solaci.org/en/2019/08/16/ffr-to-predict-cabg-result-all-benefits-in-a-population-much-too-pure/" title="Read more" >...</a>

All You Need to Know About Bolivia Sessions 2019

After 2 years, SOLACI returns to Bolivia to continue promoting the development of interventional cardiology in Latin America. Do not hesitate to participate in this important event that will undoubtedly be enriching for medical practice and, also, to improve the quality of life of patients in our region. Are you planning on participating in the<a href="https://solaci.org/en/2019/08/14/all-you-need-to-know-about-bolivia-sessions-2019/" title="Read more" >...</a>

Estenosis aórtica severa asintomática en añosos: ¿cuándo intervenir?

How to Prevent Pharmacological Overtreating in the Elderly

Cardiovascular risk increases dramatically with over the years, which almost inevitable leads to treating the elderly with statins, based on risk. To prevent over treatment, we need to identify fragile patients (bed-ridden or with dementia), whose condition might make this treatment futile on the one hand, and on the other hand, patients who regardless their<a href="https://solaci.org/en/2019/07/26/how-to-prevent-pharmacological-overtreating-in-the-elderly/" title="Read more" >...</a>

ProEducar 2019 | We celebrate 10 Years of continuous interventional education!

The ProEducar Fellow Course is a special event designed for fellows or interventional trainees seeking to update their knowledge and perfect their skills on interventional cardiology. This intensive and quality event introduces four interventional modules focused on practice rather than theory, with step-by-step demonstrations, tips and secrets of the trade, and educational cases. The course<a href="https://solaci.org/en/2019/07/21/proeducar-2019-we-celebrate-10-years-of-continuous-interventional-education/" title="Read more" >...</a>

Top